Comparative Pharmacology
Head-to-head clinical analysis: MARPLAN versus NARDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARPLAN versus NARDIL.
MARPLAN vs NARDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamine neurotransmitters (serotonin, norepinephrine, dopamine, tyramine) by inhibiting their oxidative deamination.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamines (norepinephrine, serotonin, dopamine) by inhibiting their oxidative deamination.
10 mg orally 3 times daily initially, increased to 20 mg 3 times daily; maintenance 10-20 mg 3 times daily.
Initial: 15 mg orally three times daily; increase gradually to 45-60 mg/day in divided doses; maximum 90 mg/day.
None Documented
None Documented
Terminal elimination half-life ranges from 2.5 to 4 hours, but due to irreversible inhibition of monoamine oxidase (MAO), the pharmacodynamic effect persists for up to 2-3 weeks after discontinuation until new enzyme synthesis occurs.
Terminal elimination half-life is approximately 11–13 hours; due to irreversible MAO inhibition, clinical effects persist for 1–2 weeks after discontinuation.
Primarily renal excretion of metabolites, with less than 1% excreted unchanged; approximately 60-70% of a dose is recovered in urine within 24 hours, mainly as isocarboxazide metabolites; minor biliary/fecal elimination accounts for the remainder.
Renal: 70–80% as metabolites and unchanged drug; biliary/fecal: 20–30%.
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant